Emadine

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

emedastine difumarate

Available from:

Immedica Pharma AB

ATC code:

S01GX06

INN (International Name):

emedastine

Therapeutic group:

Ophthalmologicals

Therapeutic area:

Conjunctivitis, Allergic

Therapeutic indications:

Symptomatic treatment of seasonal allergic conjunctivitis.

Product summary:

Revision: 26

Authorization status:

Authorised

Authorization date:

1999-01-27

Patient Information leaflet

                                27
B. PACKAGE LEAFLET
28
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
EMADINE 0.5 MG/ML EYE DROPS, SOLUTION
emedastine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or your pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them
even if their signs of illness are the same as yours.
-
If you get any of the side effects talk to your doctor or pharmacist.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What EMADINE is and what it is used for
2.
What you need to know before you use EMADINE
3.
How to use EMADINE
4.
Possible side effects
5.
How to Store EMADINE
6.
Contents of the pack and other information
1.
WHAT EMADINE IS AND WHAT IT IS USED FOR
EMADINE IS A MEDICINE
for the treatment of seasonal allergic conjunctivitis of the eye
(allergic
conditions of the eye). It works by reducing the intensity of the
allergic reaction.
ALLERGIC CONJUNCTIVITIS.
Some materials (allergens) like pollens, house dust or animal fur may
cause
allergic reactions resulting in itching, redness as well as swelling
of the surface of your eye.
You must talk to a doctor if you do not feel better or if you feel
worse.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE EMADINE
DO NOT USE EMADINE
•
IF YOU ARE ALLERGIC
to emedastine or any of the other ingredients of this medicine listed
in
section 6.
Ask your doctor for advice.
WARNING AND PRECAUTIONS
•
DO NOT USE EMADINE IN CHILDREN UNDER THE AGE OF 3 YEARS.
•
IF YOU WEAR CONTACT LENSES
please see section ‘EMADINE contains benzalkonium chloride
below’.
•
EMADINE IS NOT RECOMMENDED
for use in patients over 65 years of age, as it has not been
studied in clinical trials in this age group.
•
EMADINE IS NOT RECOMMENDED
for use in patients with kidney or liver problems.
Talk to your doctor or pharmacist bef
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
EMADINE 0.5 mg/ml, eye drops, solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml of solution contains emedastine 0.5 mg (as difumarate)
Excipient with known effect
Benzalkonium chloride 0.1 mg/ml
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Eye drops, solution.
Clear, colourless solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Symptomatic treatment of seasonal allergic conjunctivitis.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
EMADINE has not been studied in clinical trials beyond six weeks.
Posology
The dose is one drop of EMADINE to be applied to the affected eye(s)
twice daily.
When used with other ophthalmic medicines, an interval of ten minutes
should be allowed between
applications of each medicinal product. Eye ointments should be
administered last.
_Elderly population _
EMADINE has not been studied in elderly patients older than 65 years,
and therefore its use is not
recommended in this population.
_Paediatric population _
EMADINE may be used in paediatric patients (3 years of age and older)
at the same posology as in
adults.
_Hepatic and Renal impairment Use _
EMADINE has not been studied in these patients and therefore, its use
is not recommended in this
population.
Method of administration
For ocular use.
3
To prevent contamination of the dropper tip and solution, care should
be taken not to touch the
eyelids, surrounding areas or other surfaces with the dropper tip of
the bottle.
After cap is removed, if tamper evident snap collar is loose, remove
before using product.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Ocular corneal infiltrates
Ocular corneal infiltrates were reported in conjunction with the use
of EMADINE. In case of corneal
infiltrates, the product should be discontinued and appropriate
management should be implemented.
Excipients
Benzalkonium chloride
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 10-07-2023
Public Assessment Report Public Assessment Report Bulgarian 23-05-2014
Patient Information leaflet Patient Information leaflet Spanish 10-07-2023
Public Assessment Report Public Assessment Report Spanish 23-05-2014
Patient Information leaflet Patient Information leaflet Czech 10-07-2023
Public Assessment Report Public Assessment Report Czech 23-05-2014
Patient Information leaflet Patient Information leaflet Danish 10-07-2023
Public Assessment Report Public Assessment Report Danish 23-05-2014
Patient Information leaflet Patient Information leaflet German 10-07-2023
Public Assessment Report Public Assessment Report German 23-05-2014
Patient Information leaflet Patient Information leaflet Estonian 10-07-2023
Public Assessment Report Public Assessment Report Estonian 23-05-2014
Patient Information leaflet Patient Information leaflet Greek 10-07-2023
Public Assessment Report Public Assessment Report Greek 23-05-2014
Patient Information leaflet Patient Information leaflet French 10-07-2023
Public Assessment Report Public Assessment Report French 23-05-2014
Patient Information leaflet Patient Information leaflet Italian 10-07-2023
Public Assessment Report Public Assessment Report Italian 23-05-2014
Patient Information leaflet Patient Information leaflet Latvian 10-07-2023
Public Assessment Report Public Assessment Report Latvian 23-05-2014
Patient Information leaflet Patient Information leaflet Lithuanian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 10-07-2023
Public Assessment Report Public Assessment Report Lithuanian 23-05-2014
Patient Information leaflet Patient Information leaflet Hungarian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 10-07-2023
Public Assessment Report Public Assessment Report Hungarian 23-05-2014
Patient Information leaflet Patient Information leaflet Maltese 10-07-2023
Public Assessment Report Public Assessment Report Maltese 23-05-2014
Patient Information leaflet Patient Information leaflet Dutch 10-07-2023
Public Assessment Report Public Assessment Report Dutch 23-05-2014
Patient Information leaflet Patient Information leaflet Polish 10-07-2023
Public Assessment Report Public Assessment Report Polish 23-05-2014
Patient Information leaflet Patient Information leaflet Portuguese 10-07-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 10-07-2023
Public Assessment Report Public Assessment Report Portuguese 23-05-2014
Patient Information leaflet Patient Information leaflet Romanian 10-07-2023
Public Assessment Report Public Assessment Report Romanian 23-05-2014
Patient Information leaflet Patient Information leaflet Slovak 10-07-2023
Public Assessment Report Public Assessment Report Slovak 23-05-2014
Patient Information leaflet Patient Information leaflet Slovenian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 10-07-2023
Public Assessment Report Public Assessment Report Slovenian 23-05-2014
Patient Information leaflet Patient Information leaflet Finnish 10-07-2023
Public Assessment Report Public Assessment Report Finnish 23-05-2014
Patient Information leaflet Patient Information leaflet Swedish 10-07-2023
Public Assessment Report Public Assessment Report Swedish 23-05-2014
Patient Information leaflet Patient Information leaflet Norwegian 10-07-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 10-07-2023
Patient Information leaflet Patient Information leaflet Icelandic 10-07-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 10-07-2023
Patient Information leaflet Patient Information leaflet Croatian 10-07-2023
Public Assessment Report Public Assessment Report Croatian 23-05-2014

Search alerts related to this product

View documents history